Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
There’s no specific recommended Mounjaro diet plan. A healthy diet with Mounjaro generally consists of fresh fruits and vegetables, whole grains, and lean proteins. Avoiding foods high in ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Weight loss drugs are seen as an easy option for dropping the pounds, but they are also expensive, and can have nasty side ...
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...
Evening Standard on MSN1d
Celebrities who’ve used Ozempic: Oprah Winfrey, James Corden, and moreWhile talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback